KromaTiD uses single-cell, hybridization-based analysis to help gene and cell therapy developers bolster safety data packages for both research and regulatory filings. Our proprietary platform, directional Genomic Hybridization (dGH), enables researchers to assess the effects of their treatments using both localized and unbiased techniques for the most comprehensive genomic structural analysis available.
KromaTiD, Inc.
KromaTiD uses single-cell, hybridization-based analysis to help gene and cell therapy developers bolster safety data for both research and regulatory filings.
